PDS Biotechnology

Yahoo Finance • 14 days ago

PDS Biotech outlines accelerated regulatory timeline after VERSATILE-003 protocol amendment

Earnings Call Insights: PDS Biotechnology Corporation (PDSB) Q4 2025 MANAGEMENT VIEW * Frank Bedu-Addo, President, CEO & Director, detailed that "the fourth quarter of 2025 capped a period of important progress for PDS Biotech, marked... Full story

Yahoo Finance • 15 days ago

Earnings week ahead: NKE, TLRY, SPCE, BYND, NNDM, CAG, and more

[Nest of Eggs] LindaJoHeilman As the calendar turns from March to April, a holiday-shortened week still delivers a diverse set of earnings with the potential to offer fresh directional cues. Consumer and brand momentum will be in focus w... Full story

Yahoo Finance • 4 months ago

PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)

PRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers,... Full story

Yahoo Finance • 5 months ago

PDS Biotechnology price target lowered to $3 from $5 at B. Riley

B. Riley lowered the firm’s price target on PDS Biotechnology (PDSB) to $3 from $5 and keeps a Buy rating on the shares. The shares remain attractively valued with near-zero EV that fails to reflect impact of this recent strategic pivot on... Full story

Yahoo Finance • 5 months ago

PDS Biotechnology GAAP EPS of -$0.19 beats by $0.01

* PDS Biotechnology press release [https://seekingalpha.com/pr/20305887-pds-biotech-reports-third-quarter-2025-financial-results-and-provides-clinical-programs] (PDSB [https://seekingalpha.com/symbol/PDSB]): Q3 GAAP EPS of -$0.19 beats by... Full story

Yahoo Finance • 5 months ago

PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

Company Announced Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Cancer Phase 2 Results Lead Company to Seek Expedited Approval Pathway in Ongoing VERSATILE-003 P... Full story

Yahoo Finance • 5 months ago

PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapy PDS01ADC reprograms natural killer (NK) cells to possess characteristics that make them more active in killing ca... Full story

Yahoo Finance • 5 months ago

PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer

Company aims to shorten time frame to make PDS0101 available to patients with HPV16-positive head and neck cancer, projected to be the most dominant type of head and neck cancer in the US by mid 2030s Proposed Amendment to Ongoing VERSATI... Full story

Yahoo Finance • 7 months ago

PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population

First combination therapy to report 29.5 months of Median Overall Survival (mOS); Standard of care Keytruda® (pembrolizumab) alone (10.8 months) and Keytruda® + chemotherapy (12.3 months) in patients with CPS 1-19* Encouraging efficacy si... Full story

Yahoo Finance • 8 months ago

PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer

Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of care pembrolizumab or pembrolizumab + chemotherapy is 17.9 months* VERSATILE-003 Phase 3 trial in progress PRINCETON, N.J., Au... Full story

Yahoo Finance • 8 months ago

Earnings call transcript: PDS Biotech Q2 2025 reports narrower EPS loss, stock rises

PDS Biotechnology Corp (PDSB) reported a narrower-than-expected loss in its second quarter earnings for 2025, with an EPS of -$0.21, slightly beating the forecast of -$0.22. The company’s stock responded positively, showing a premarket inc... Full story

Yahoo Finance • 8 months ago

PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) Reports Narrower Q2 2025 Loss, Stock Rises on Clinical Progress

PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB [https://www.chartmill.com/stock/quote/PDSB/profile]) reported its second-quarter 2025 financial results, with earnings per share (EPS) of -$0.21, slightly better than the analyst consensus estimate of -... Full story

Yahoo Finance • 8 months ago

PDS Biotechnology GAAP EPS of -$0.21 beats by $0.02

* PDS Biotechnology press release [https://seekingalpha.com/pr/20199124-pds-biotech-reports-second-quarter-2025-financial-results-and-provides-clinical-programs] (NASDAQ:PDSB [https://seekingalpha.com/symbol/PDSB]): Q2 GAAP EPS of -$0.21... Full story

Yahoo Finance • 9 months ago

PDS Biotechnology stock advances as Phase 2 trial meets expansion criteria

Investing.com - PDS Biotechnology Corp (NASDAQ:PDSB), currently valued at $59.4 million, has completed patient recruitment for Stage 1 of a clinical trial evaluating its PDS01ADC therapeutic in metastatic colorectal cancer (mCRC), meeting... Full story

Yahoo Finance • 10 months ago

PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

Event to Discuss the Changing Landscape of HNSCC in context with the Merck KN-689 study and the Rapidly Increasing Incidences of HPV16-positive HNSCC in the United States and Europe Webinar to be held Tuesday, June 17, 2025, 12:00 PM ET... Full story

Yahoo Finance • 11 months ago

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Phase 2: Versamune® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC - Median overall survival for CPS ≥20 is 39.3 months - Median overall survival for CPS ≥1 is 30.0 months Phase 3: Versamune® HPV with pembrolizumab a... Full story

Yahoo Finance • 11 months ago

PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase

PRINCETON, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers,... Full story

Yahoo Finance • 12 months ago

PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

PRINCETON, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers... Full story

Yahoo Finance • 12 months ago

PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting

PRINCETON, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers... Full story

Yahoo Finance • last year

PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

NCI presentation to highlight IL-12 fused antibody drug conjugate during poster presentation PRINCETON, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage... Full story